{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:36:52Z","timestamp":1760243812359,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T00:00:00Z","timestamp":1307577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that occurred in clinical trials with the single-agent plitidepsin. Demographic, clinical and pharmacological variables were explored by univariate and multivariate logistic regression analysis. Forty-six of 578 treated patients (8.0%) had at least one CAE (11 patients (1.9%) with plitidepsin-related CAEs), none with fatal outcome as a direct consequence. The more frequent CAEs were rhythm abnormalities (n = 31; 5.4%), mostly atrial fibrillation\/flutter (n = 15; 2.6%). Of note, life-threatening ventricular arrhythmias did not occur. Myocardial injury events (n = 17; 3.0%) included possible ischemic-related and non-ischemic events. Other events (miscellaneous, n = 6; 1.0%) were not related to plitidepsin. Significant associations were found with prostate or pancreas cancer primary diagnosis (p = 0.0017), known baseline cardiac risk factors (p = 0.0072), myalgia present at baseline (p = 0.0140), hemoglobin levels lower than 10 g\/dL (p = 0.0208) and grade \u22652 hypokalemia (p = 0.0095). Treatment-related variables (plitidepsin dose, number of cycles, schedule and\/or total cumulative dose) were not associated. Electrocardiograms performed before and after plitidepsin administration (n = 136) detected no relevant effect on QTc interval. None of the pharmacokinetic parameters analyzed had a significant impact on the probability of developing a CAE. In conclusion, the most frequent CAE type was atrial fibrillation\/atrial flutter, although its frequency was not different to that reported in the age-matched healthy population, while other CAEs types were rare. No dose-cumulative pattern was observed, and no treatment-related variables were associated with CAEs. Relevant risk factors identified were related to the patient\u2019s condition and\/or to disease-related characteristics rather than to drug exposure. Therefore, the current analysis supports a safe cardiac risk profile for single-agent plitidepsin in cancer patients.<\/jats:p>","DOI":"10.3390\/md9061007","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T15:42:46Z","timestamp":1307634166000},"page":"1007-1023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis"],"prefix":"10.3390","volume":"9","author":[{"given":"Arturo","family":"Soto-Matos","sequence":"first","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Szyldergemajn","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Extremera","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Miguel-Lillo","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinthya","family":"Coronado","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Lardelli","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Roy","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Silvia","family":"Corrado","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Pharma Mar S.A., Colmenar Viejo, Madrid 28770, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2011,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","article-title":"Cardiotoxicity of cancer therapy","volume":"23","author":"Floyd","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects","volume":"25","author":"Carver","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s12325-009-0048-z","article-title":"Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer","volume":"26","author":"Fiuza","year":"2009","journal-title":"Adv. Ther"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488610789869111","article-title":"Antineoplastic chemotherapy induced QTc prolongation","volume":"5","author":"Bagnes","year":"2010","journal-title":"Curr. Drug Saf"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1634\/theoncologist.7-1-65","article-title":"The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: Is there cause for concern?","volume":"7","author":"Keefe","year":"2002","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00520-007-0397-6","article-title":"Detection and monitoring of cardiotoxicity-what does modern cardiology offer?","volume":"16","author":"Jurcut","year":"2008","journal-title":"Support. Care Cancer"},{"key":"ref_10","first-page":"248086q","article-title":"Novel antiviral and cytotoxic agent. PCT Int. Pat. Appl. WO 91.04985, 18 April 1991; GB Appl. 89\/22,026, 29 September 1989","volume":"115","author":"Rinehart","year":"1991","journal-title":"Chem. Abstr"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bjc.1998.570","article-title":"In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells","volume":"78","author":"Depenbrock","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation","volume":"13","author":"Suarez","year":"2006","journal-title":"Cell Death Differ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","article-title":"Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta","volume":"21","author":"Losada","year":"2002","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/sj.onc.1207636","article-title":"JNK activation is critical for Aplidin-induced apoptosis","volume":"23","author":"Cuadrado","year":"2004","journal-title":"Oncogene"},{"key":"ref_15","unstructured":"Mu\u00f1oz, MJ, Alvarez, E, Martinez, T, Gonzalez-Santiago, L, Sasak, H, Lepage, D, Aviles, P, and Mu\u00f1oz, A (Proceedings of the 2007 AACR Annual Meeting, 2007). JNK activation as an in vivo marker of Aplidin\u00ae Activity, Proceedings of the 2007 AACR Annual Meeting, Abstract 5580."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdi311","article-title":"VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia","volume":"16","author":"Biscardi","year":"2005","journal-title":"Ann. Oncol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1038\/sj.bjc.6601864","article-title":"Antiangiogenic activity of aplidine, a new agent of marine origin","volume":"90","author":"Taraboletti","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2402788","article-title":"Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4","volume":"17","author":"Broggini","year":"2003","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother. Pharmacol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies","volume":"23","author":"Faivre","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","article-title":"Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115","volume":"17","author":"Maroun","year":"2006","journal-title":"Ann. Oncol"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-07-1652","article-title":"Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors","volume":"14","author":"Izquierdo","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/md7010057","article-title":"Phase II randomized study of Plitidepsin (Aplidin), alone or in association with l-carnitine, in patients with unresectable advanced renal cell carcinoma","volume":"7","author":"Schoffski","year":"2009","journal-title":"Mar. Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2008.06.017","article-title":"Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer","volume":"64","author":"Eisen","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CMR.0b013e32832bbde6","article-title":"Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma","volume":"19","author":"Eisen","year":"2009","journal-title":"Melanoma Res"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/md7030451","article-title":"Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium","volume":"7","author":"Dumez","year":"2009","journal-title":"Mar. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/COC.0b013e31819fdf5e","article-title":"Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma","volume":"33","author":"Baudin","year":"2010","journal-title":"Am. J. Clin. Oncol"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.lungcan.2007.10.019","article-title":"Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer","volume":"60","author":"Peschel","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","article-title":"Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma","volume":"16","author":"Mateos","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"ref_30","unstructured":"Ferme, C, Mateos, MV, Szyldergemajn, S, Zucca, E, Giani, AM, and Ribrag, V (2010). Proceedings of T-Cell Lymphoma Forum."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"ref_34","first-page":"106a","article-title":"Phase I clinical and pharmacokinetic study of the marine compound aplidine (APL) administered as a 3 hour infusion every 2 weeks","volume":"21","author":"Ciruelos","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-008-0841-4","article-title":"Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects","volume":"64","author":"Valenzuela","year":"2009","journal-title":"Cancer Chemother. Pharmacol"},{"key":"ref_36","unstructured":"Roche, B (2007). Exploratory Study of the Effects of Escalating Doses of Aplidin on: RR, QTc, VP\/dtmax and dLVP\/dtmin in a Guinea Pig Langendorff Preparation, QTest Labs. unpublished work."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"(2009). Registry of Atrial Tachycardia and Atrial Fibrillation Episodes in the cardiac rhythm management device population: The RATE Registry design. Am Heart J, 157, 983\u2013987.e1.","DOI":"10.1016\/j.ahj.2009.03.017"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0002-9149(99)80412-3","article-title":"Prevalence and prognostic significance of exercise-induced supraventricular tachycardia in apparently healthy volunteers","volume":"75","author":"Maurer","year":"1995","journal-title":"Am. J. Cardiol"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2146\/ajhp100148","article-title":"Prevalence pathogenesis, and impact of atrial fibrillation","volume":"67","author":"Sanoski","year":"2010","journal-title":"Am. J. Health Syst. Pharm"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a058207","article-title":"Prognostic factors in hormone-resistant progressing cancer of the prostate","volume":"3","author":"Fossa","year":"1992","journal-title":"Ann. Oncol"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1055-9965.EPI-09-0322","article-title":"Serum creatinine and prostate cancer risk in a prospective study","volume":"18","author":"Weinstein","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.amjsurg.2005.08.029","article-title":"Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis","volume":"191","author":"Tessler","year":"2006","journal-title":"Am. J. Surg"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ctrv.2006.04.008","article-title":"Cancer-related anaemia management in the 21st century","volume":"32","author":"Pronzato","year":"2006","journal-title":"Cancer Treat. Rev"},{"key":"ref_44","first-page":"172","article-title":"Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia","volume":"71","author":"Kishi","year":"2000","journal-title":"Int. J. Hematol"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2005.11.001","article-title":"Anticancer agents and cardiotoxicity","volume":"33","author":"Ng","year":"2006","journal-title":"Semin. Oncol"}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/9\/6\/1007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:56:21Z","timestamp":1760219781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/9\/6\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,9]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6]]}},"alternative-id":["md9061007"],"URL":"https:\/\/doi.org\/10.3390\/md9061007","relation":{},"ISSN":["1660-3397"],"issn-type":[{"type":"electronic","value":"1660-3397"}],"subject":[],"published":{"date-parts":[[2011,6,9]]}}}